Promis Neurosciences (PMN) Stock
Early stage biotech developing treatments for Alzheimer’s and ALS. Here's the price, business snapshot, and what's worth knowing about Promis Neurosciences in October 2026.
ProMIS Neurosciences Inc (PMN) is a clinical-stage biotechnology company developing targeted immunotherapies for neurodegenerative diseases such as Alzheimer’s and ALS. The company’s approach centres on proprietary antibodies designed to recognise disease‑specific, misfolded protein conformations while avoiding normal forms, aiming to reduce off‑target effects. As a small‑cap, early‑stage issuer with a market capitalisation of roughly $23.7m, ProMIS currently has limited or no product revenues and is dependent on clinical trial progress, partner collaborations and financing to advance programmes. Investment outcomes hinge on binary clinical readouts, regulatory milestones and the company’s ability to manage cash runway, so share price volatility can be high. Investors should treat exposure as speculative, do their own research, consider time horizon and risk tolerance, and note that past performance is not a guide to future returns. This summary is educational only and not personalised investment advice.
